The takeover of Nordion Inc , the Canadian medical isotope supplier, has run into a speed bump as U.S. antitrust regulators requested further information from Nordion and its suitor Sterigenics, in order to approve the deal. In a brief statement on Friday, Nordion said it has received a request for additional information from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Act. The "Second Request" extends the waiting period imposed by the act until 30 days after Nordion and Sterigenics have complied with the request.Nordion, a leading producers of molybdenum-99, an isotope used in medical imaging, said it still expects the $805 million deal to close in the second half of 2014.Sterigenics, a sterilization services provider owned by private equity firm GTCR LLC, twice sweetened its bid for Nordion in order to clinch a deal, after Nordion twice received rival proposals from an unnamed buyer.
Nordion Inc. (Nordion) is a global health science company, engaged providing products and services used for the prevention, diagnosis and treatment of disease. Shares of NDN fell by 0.59% or $-0.08/share to $13.56. In the past year, the shares have traded as low as $7.29 and as high as $14.27. On average, 222757 shares of NDN.TO exchange hands on a given day and today's volume is recorded at 8044.
Nordion Inc. (Nordion) is a global health science company, engaged providing products and services used for the prevention, diagnosis and treatment of disease. Shares of NDZ remained unchanged at $12.67. In the past year, the shares have traded as low as $7.15 and as high as $12.98. On average, 1482800 shares of NDZ exchange hands on a given day and today's volume is recorded at 0.
Source
